ICT v1.0
Research type
Research Study
Full title
Immunogenecity of Cellular Therapies
IRAS ID
289363
Contact name
Joanne Jones
Contact email
Sponsor organisation
University of Cambridge
Duration of Study in the UK
9 years, 11 months, 31 days
Research summary
Regenerative medicines aim to replace damaged or diseased tissues, and thereby find better treatments or cures for illness that currently cannot be treated. At present two different approaches are being tested – one is to stimulate the body’s own cells to repair damaged tissue, the other is to transplant new cells into the body. In the case of transplantation this typically involves transplanting cells from one individual into another.
Currently it is not known if these cells (called “cell therapies”) will be rejected by the patient– in the way a solid organ transplant (such as a kidney or liver) would be if they weren’t “matched”. It is also unclear if patients receiving cell therapies need to take immunosuppressants to prevent rejection.
The aim of this study is to determine if cell therapies activate the immune system when tested in the laboratory. If they do, it is likely that they will be rejected when given to patientsREC name
East of England - Essex Research Ethics Committee
REC reference
21/EE/0051
Date of REC Opinion
11 Feb 2021
REC opinion
Further Information Favourable Opinion